Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model
ABSTRACT: Background: Drug regulatory agencies (DRA) support prescription of generic products of intravenous antibiotics assuming therapeutic equivalence from pharmaceutical equivalence. Recent reports of deaths associated with generic heparin and metoprolol have raised concerns about the efficacy a...
- Autores:
-
Zuluaga Salazar, Andrés Felipe
Agudelo Pérez, María
Rodríguez Jaramillo, Carlos Andrés
Vesga Meneses, Omar
Cárdeno Sánchez, John Jairo
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2010
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/39095
- Acceso en línea:
- https://hdl.handle.net/10495/39095
- Palabra clave:
- Antiinfecciosos
Anti-Infective Agents
Infecciones Bacterianas - Complicaciones
Bacterial Infections - complications
Modelos Animales de Enfermedad
Disease Models, Animal
Medicamentos Genéricos
Drugs, Generic
Gentamicinas
Gentamicins
Pruebas de Sensibilidad Microbiana
Microbial Sensitivity Tests
Neutropenia
Organ Specificity
Equivalencia Terapéutica
Therapeutic Equivalency
Muslo
Thigh
Especificidad de Órganos
https://id.nlm.nih.gov/mesh/D000890
https://id.nlm.nih.gov/mesh/D001424
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D016568
https://id.nlm.nih.gov/mesh/D005839
https://id.nlm.nih.gov/mesh/D008826
https://id.nlm.nih.gov/mesh/D009503
https://id.nlm.nih.gov/mesh/D009928
https://id.nlm.nih.gov/mesh/D013810
https://id.nlm.nih.gov/mesh/D013848
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
| Summary: | ABSTRACT: Background: Drug regulatory agencies (DRA) support prescription of generic products of intravenous antibiotics assuming therapeutic equivalence from pharmaceutical equivalence. Recent reports of deaths associated with generic heparin and metoprolol have raised concerns about the efficacy and safety of DRA-approved drugs. Methodology/Principal Findings: To challenge the assumption that pharmaceutical equivalence predicts therapeutic equivalence, we determined in vitro and in vivo the efficacy of the innovator product and 20 pharmaceutically equivalent generics of gentamicin. The data showed that, while only 1 generic product failed in vitro (MIC = 45.3 vs. 0.7 mg/L, P,0.05), 10 products (including gentamicin reference powder) failed in vivo against E. coli due to significantly inferior efficacy (Emax = 4.81 to 5.32 vs. 5.99 log10 CFU/g, P#0.043). Although the design lacked power to detect differences in survival after thigh infection with P. aeruginosa, dissemination to vital organs was significantly higher in animals treated with generic gentamicin despite 4 days of maximally effective treatment. Conclusion: Pharmaceutical equivalence does not predict therapeutic equivalence of generic gentamicin. Stricter criteria based on solid experimental evidence should be required before approval for human use. |
|---|
